Title : Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.

Pub. Date : 2019 Apr

PMID : 30610588






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Thus, we hypothesized that the addition of metformin to everolimus and exemestane, could lead to better outcomes in overweight and obese patients with metastatic, hormone receptor-positive, HER2-negative breast cancer. Metformin erb-b2 receptor tyrosine kinase 2 Homo sapiens
2 We conducted a phase II trial to evaluate the efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal women with metastatic, hormone receptor-positive, HER2-negative breast cancer. Metformin erb-b2 receptor tyrosine kinase 2 Homo sapiens
3 Conclusion The combination of metformin, everolimus and exemestane was safe and had moderate clinical benefit in overweight and obese with patients metastatic, hormone receptor-positive, HER2-negative breast cancer. Metformin erb-b2 receptor tyrosine kinase 2 Homo sapiens